



## **Crescendo Biologics' CEO, Peter Pack to present and participate in panel at Biotech and Money 2017**

**Cambridge, UK, 6 February 2017** – Crescendo Biologics Limited (Crescendo), the drug developer of Humabody® therapeutics, today announces its CEO, Peter Pack will be taking part in a panel discussion during Biotech and Money 2017, London, UK. Peter will also give a company presentation during the Investable track, covering a number of topics including Crescendo's recent deal with Takeda, the Company's preclinical pipeline and its proprietary transgenic platform.

Details of Crescendo's presentation and panel participation are as follows:

### **Panel**

Title: 'Anatomy of an...' Innovative Deal Structure

Date: Tuesday 7 February 2017

Time: 09:50

Location: Broadgate 2, etc. Venues, 155 Bishopsgate, London, EC2M 3YD

### **Company presentation**

Track: Investable

Date: Tuesday 7 February 2017

Time: 16:15

Location: Broadgate 1, etc. Venues, 155 Bishopsgate, London, EC2M 3YD

For more information on Crescendo's presentation or for media enquiries, please contact [crescendo@instinctif.com](mailto:crescendo@instinctif.com).

**Ends**

**For more information, please contact:**

<b>Crescendo Biologics</b> <b>Dr Peter Pack, CEO</b>	<b>Tel:44 (0)1223 497140</b> <b>info@crescendobiologics.com</b>
<b>Instinctif Partners</b> <b>Dr Christelle Kerouedan / Melanie Toyne-Sewell</b>	<b>Tel:44 (0)20 7457 2020</b> <b>crescendo@instinctif.com</b>



## **Notes to Editors:**

### **About Crescendo Biologics Ltd**

Crescendo Biologics is a biopharmaceutical company discovering and developing potent, highly differentiated mono- and multi-specific Humabody<sup>®</sup> therapeutics in oncology. The Company's Humabody<sup>®</sup> therapeutics are based on its unique, patent protected, transgenic mouse platform generating 100% human V<sub>H</sub> domain building blocks (Humabody<sup>®</sup> V<sub>H</sub>) with superior biophysical properties.

Crescendo is pursuing novel Humabody<sup>®</sup>-based product opportunities, through in-house development and strategic partnerships in both multi-specific immuno-oncology modulators and HDCs (Humabody<sup>®</sup> Drug Conjugates), the next generation of ADCs.

Crescendo is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Touchstone Innovations (formerly known as Imperial Innovations) and Takeda.

For more information, please visit the website: [www.crescendobiologics.com](http://www.crescendobiologics.com) .